ABPI response to NICE process review

04 February 2021 Posted in News by Press Office

NICE has launched a public consultation on proposals for changes to the processes it uses to develop its guidance on medicines, medical devices, diagnostics and digital health technologies.

We should use the opportunity of the process review to deliver greater consistency, predictability, and rigour in how companies experience working with NICE in the future. Dr Paul Catchpole

In response, Dr Paul Catchpole, ​Director of Value and Access Policy at the ABPI, said:

“We should use the opportunity of the process review to deliver greater consistency, predictability, and rigour in how companies experience working with NICE in the future.

“This will include making sure there are efficient and timely engagement mechanisms throughout appraisals so that the right decisions are made for patients, at the right time.”

TAGS
  • NICE

Last modified: 20 September 2023

Last reviewed: 20 September 2023

The ABPI exists to make the UK the best place in the world to research, develop and use new medicines. We represent companies of all sizes who invest in discovering the medicines of the future. 

Our members supply cutting edge treatments that improve and save the lives of millions of people. We work in partnership with Government and the NHS so patients can get new treatments faster and the NHS can plan how much it spends on medicines. Every day, we partner with organisations in the life sciences community and beyond to transform lives across the UK.

Media enquiries

+44 (0) 20 7747 7147​​